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Streptococcus pneumoniae is the leading cause of morbidity and 
mortality due to community acquired pneumonia, bacterial meningitis 
and bacteraemia worldwide. Pneumococcal conjugate vaccines 
protect against invasive disease, but are expensive to manufacture, 
limited in serotype coverage, associated with serotype replacement, 
and demonstrate reduced effectiveness against mucosal colonisation.  
For Malawi, nasopharyngeal carriage of vaccine-type pneumococci is 
common in vaccinated children despite national roll-out of 13-valent 
pneumococcal conjugate vaccine (PCV13) since 2011. Our team has 
safely transferred an established experimental human pneumococcal 
carriage method from Liverpool School of Tropical Medicine to the 
Malawi-Liverpool Wellcome Trust Clinical Research Programme, 
Malawi. 
This study will determine potential immunological mechanisms for the 
differential effects of PCV13 on nasal carriage between healthy 
Malawian and UK populations. We will conduct a double-blinded 
randomised controlled trial to vaccinate (1:1) participants with either 
PCV13 or control (normal saline). After a period of one month, 
Open Peer Review
Reviewer Status  AWAITING PEER REVIEW
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 19
Wellcome Open Research 2021, 6:240 Last updated: 15 NOV 2021
participants will be inoculated with S. pneumoniae serotype 6B to 
experimentally induce nasal carriage using the EHPC method. 
Subsequently, participants will be invited for a second inoculation 
after one year to determine longer-term vaccine-induced 
immunological effects. Primary endpoint: detection of inoculated 
pneumococci by classical culture from nasal wash recovered from the 
participants after pneumococcal challenge. Secondary endpoints: local 
and systemic innate, humoral and cellular responses to PCV-13 with 
and without pneumococcal nasal carriage 
The primary objective of this controlled human infection model study 
is to determine if PCV-13 vaccination is protective against 
pneumococcal carriage in healthy adult Malawian volunteers. This 
study will help us to understand the observed differences in PCV-13 
efficacy between populations and inform the design of future vaccines 
relevant to the Malawian population. 
Trial Registration: Pan African Clinical Trial Registry (REF: 
PACTR202008503507113)
Keywords 
Streptococcus pneumoniae, Pneumococcal carriage, Experimental 
medicine, pneumonia, vaccine, controlled human infection model, 
nasal colonisation, global health
 
This article is included in the Malawi-Liverpool 
Wellcome Trust Clinical Research Programme 
gateway.
 
Page 2 of 19
Wellcome Open Research 2021, 6:240 Last updated: 15 NOV 2021
Corresponding authors: Ben Morton (ben.morton@lstmed.ac.uk), Stephen B. Gordon (sgordon@mlw.mw)
Author roles: Morton B: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project 
Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & 
Editing; Jambo K: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Software, 
Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Chikaonda T: Conceptualization, 
Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation, 
Writing – Review & Editing; Rylance J: Conceptualization, Funding Acquisition, Investigation, Supervision, Writing – Review & Editing; 
Henrion MYR: Conceptualization, Formal Analysis, Methodology, Supervision, Writing – Review & Editing; Banda NP: Data Curation, 
Investigation, Methodology, Supervision, Writing – Review & Editing; Nsomba E: Investigation, Methodology, Project Administration, 
Supervision, Validation, Writing – Review & Editing; Gondwe J: Data Curation, Formal Analysis, Investigation, Project Administration, 
Resources, Software, Validation, Writing – Review & Editing; Ferreira D: Conceptualization, Investigation, Resources, Supervision, Writing 
– Review & Editing; Gordon SB: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, 
Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review 
& Editing;
Competing interests: No competing interests were disclosed.
Grant information: This work is supported by a Wellcome Trust grant (211433/Z/18/Z) and the study is sponsored by The Liverpool 
School of Tropical Medicine (20-021). The funder and sponsor have no role in study design; collection, management, analysis, and 
interpretation of data; writing of the report; or the decision to submit the report for publication. Neither do they have ultimate authority 
over any of these activities. 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2021 Morton B et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Morton B, Jambo K, Chikaonda T et al. The influence of pneumococcal conjugate vaccine-13 on nasal 
colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised 
controlled trial protocol [version 1; peer review: awaiting peer review] Wellcome Open Research 2021, 6:240 
https://doi.org/10.12688/wellcomeopenres.17172.1
First published: 20 Sep 2021, 6:240 https://doi.org/10.12688/wellcomeopenres.17172.1 
 
Page 3 of 19
Wellcome Open Research 2021, 6:240 Last updated: 15 NOV 2021
Abbreviations
AE: Adverse Event; CAP: Community Acquired Pneumonia; 
CFU: Colony Forming Units; CHIM: Controlled Human Infec-
tion Model; CRF: Case Report Form; DSMB: Data, Safety and 
Monitoring Board; EHPC: Experimental Human Pneumococcal 
Colonisation; ELISA: Enzyme-Linked Immunosorbent Assay; 
ELISPOT: Enzyme-Linked Immune Absorbent Spot; FBC: 
Full Blood Count; GCP: Good Clinical Practice; HIV: Human 
Immunodeficiency Virus; HTS: Human immunodeficiency 
virus Testing Service; ICH-GCP: International Conference on 
Harmonisation of Good Clinical Practice; LSTM: Liverpool 
School of Tropical Medicine; MARVELS: Malawi Acceler-
ated Research in Vaccines, Experimental and Laboratory Sys-
tems; MHRA; Medicines and Healthcare products Regulatory 
Authority (UK Regulator); MK: Malawian Kwacha; MLW: 
Malawi-Liverpool Wellcome Trust Clinical Research Programme 
Laboratories; MTA: Material Transfer Agreement; NHSRC: 
National Health Sciences Research Committee; OM: Otitis Media; 
PBMC: Peripheral Blood Mononuclear Cell; PCR: Polymerase 
Chain Reaction; PCV: Pneumococcal conjugate vaccines; PCV13: 
Pneumococcal conjugate vaccine 13; PCVPA: Pneumococcal 
Carriage in Vulnerable Populations in Africa; PMPB: Pharmacy, 
Medicines and Poisons Board; QECH: Queen Elizabeth Central 
Hospital; RNA: Ribonucleic Acid; SAE: Serious Adverse Event; 
SOP: Standardised Operating Procedure; SUSAR: Serious 
Unexpected Serious Adverse Reaction; TSC: Trial Steering 
Committee.
Introduction
Streptococcus pneumoniae remains a major public health threat 
worldwide, particularly in low- to middle-income countries1. 
Despite the introduction of pneumococcal conjugate vaccines 
(PCV), there remain more than 500,000 pneumococcal deaths 
in children 0–59 months old per year2. The introduction PCVs 
coincided with a 51% reduction in pneumococcal deaths 
between 2000 and 2015 but these remain expensive to manufac-
ture, have limited serotype coverage, with evidence of serotype 
replacement and have reduced efficacy against mucosal 
colonisation (13–20%) compared to invasive disease3. In 
Malawi, nasopharyngeal carriage of vaccine-type pneumococci 
is common in vaccinated children despite national roll-out of 
13-valent pneumococcal conjugate vaccine (PCV13) since 20114. 
Cost-effectiveness estimates for PCV-13 vaccination are based 
strongly on improved herd immunity through reduced carriage 
(reservoir for infection transmission) in vaccinated children5.
We established a safe and reproducible Controlled Human 
Infection Model (CHIM) at the Liverpool School of Tropical 
Medicine (LSTM), UK. This model has been used to test the 
effect of PCV-13 versus control (Hepatitis A) vaccination in a 
Phase III trial6. Importantly, we found that PCV-13 induces 
protection against controlled infection model induced car-
riage in the UK6. This finding was entirely consistent with the 
observed impact of PCV-13 on nasal carriage at the UK and US 
population level. Most recently, we have successfully trans-
ferred operating procedures from the LSTM model and safely 
adapted these for the Malawian context (National Health 
Sciences Research Committee [NHSRC]: 19/08/2246)7.
Our feasibility study of pneumococcal controlled human 
infection in Malawi7 has demonstrated no SAEs or AEs and mini-
mal symptoms for participants who completed the programme8. 
We have confirmed LSTM procedures and successfully adapted 
standard operating procedures for in-country use. Our observed 
nasal carriage rates after inoculation of 3/9 (33%) and 4/9 at the 
20,000 and 80,000 CFU doses, respectively. The 4/9 carriage rate 
at 80,000 CFUs met our predefined study stopping criteria4 to 
confirm CHIM feasibility. This confirms that the 80,000 CFU 
pneumococcal dose used by LSTM to test vaccines in the UK 
is relevant to populations within Malawi8. Based on success-
ful transfer of procedures, we are confident that our clinical and 
laboratory procedures are sufficiently robust to test vaccine 
efficacy. Our robust social science led exploration of accept-
ability has demonstrated that participants feel safe, cared for and 
were proud to be involved with this research programme9.
This study will initially confirm if the epidemiological 
observation of vaccine-type pneumococcal carriage in vacci-
nated children in Malawi is mirrored by a diminished impact of 
PCV13 in reducing nasopharyngeal carriage in healthy adults 
in Malawi compared to the UK. It is likely that this will be the 
case as the intensity of community exposure, environmental 
conditions and host immunological history are very differ-
ent in Malawi compared to the UK. It is possible, however, that 
the adult model will not show this reduced efficacy in which case 
we will have to refine our study population to more accurately 
reflect the populations of interest. In the event that reduced vac-
cine efficacy is seen in the Malawi CHIM model, we will then 
determine potential immunological mechanisms for the differen-
tial effects of PCV-13 on nasal carriage between healthy Malawian 
and UK populations.
The burden of both nasal carriage rates10 and invasive infection2 
are much higher in Malawian compared to UK populations. 
As above, increased background exposure to pneumococ-
cus is a potential mechanism for reduced vaccine efficacy11. 
Therefore, we will test vaccine effectiveness against a sequentially 
increased pneumococcal exposure dose of 20,000, 80,000 and 
160,000 colony forming units per nostril. The 160,000 dose has 
been safely administered in Liverpool with no observed adverse 
events12. Further, PCV-13 induced serotype-specific antibody 
concentrations are known to wane in the months following 
primary vaccination, potentially becoming too low to prevent 
invasive disease in vulnerable groups13. We will therefore invite 
participants to test vaccine efficacy at twelve months after 
vaccination with a second 80,000 cfu/nostril challenge with 
pneumococcus to determine longer-term immune responses in the 
PCV-13 vaccinated group. Previous nasal carriage is known to be 
protective against re-challenge12. Therefore, we will also invite 
participants from the control vaccine group for re-challenge at 
12-months to differentiate whether any continued protective 
effects are vaccine or carriage induced. We will directly compare 
data generated from this Malawian study with existing UK data6 
to compare immunological parameters and define the mechanisms 
for observed differences in vaccine-mediated effects between 
the two populations.
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There is an urgent need to develop new vaccines directed to 
the Malawian population. We will determine immunological 
responses to PCV-13 against a relevant pneumococcal challenge 
(6B is a vaccine serotype) in Malawi and contrast these with 
existing data from a completed UK study (study design, CHIM 
and vaccines directly comparable). This information will 
help us to understand the observed differences in PCV-13 efficacy 
between populations and inform the design of future vaccines 
relevant to the Malawian population.
Ethical considerations for controlled human infection 
studies in low income settings
We conducted extensive preliminary work as a precursor to 
the introduction of the pneumococcal controlled human infec-
tion model to Malawi. This included extensive stakeholder 
consultation14 and detailed exploration of community knowl-
edge and views regarding the CHIM of pneumococcal car-
riage in Malawi15. Following on from this, we interviewed 
participants during our feasibility study to assess acceptability 
and determine ways to optimise their experience9.
Study protocol (V1.2, 16th Dec 2020)
Main objective
Determine if PCV-13 vaccination is protective against 
experimental human pneumococcal carriage (EHPC) using a 
CHIM in healthy adult Malawian volunteers and compare the 
level of protection with that observed in the same CHIM in 
Liverpool, UK.
Secondary objectives
     1.     Determine how pneumococcal dose influences carriage in 
PCV-13 vaccinated adults
     2.     Determine PCV-13 protection against pneumococcal 
re-challenge 12-months post vaccination
     3.     Determine the protective effect of prior pneumococcal 
carriage in Malawian volunteers
     4.     Examine local and systemic innate, humoral and 
cellular responses to PCV-13 with and without pneumococcal 
nasal carriage
     5.     Explore participant experience in the study to monitor 
acceptability
Study hypothesis
Vaccination with PCV-13 will reduce nasal carriage by 40% 
compared to control vaccination with normal (0.9%) saline 
(from baseline of 60% carriage to 36% carriage) in participants 
challenged with pneumococcus at a dose of 80,000 cfu/naris.
Study design
A double-blinded randomised controlled trial of adult healthy 
human participants experimentally exposed to escalating doses 
of S. pneumoniae in the nasopharynx. The intervention vaccine 
will be PCV-13 (Prevnar-13) and the control vaccine will be 
normal (0.9%) saline. We will closely monitor study participants 
to ensure safety and tolerability of study procedures. We will 
measure immune protective responses to S. pneumoniae chal-
lenge using mucosal (nasal, throat and saliva) and blood samples. 
We will invite participants for re-challenge 12-months after 
vaccination to determine longer-term immunological responses.
This study is based on the foundation of our ethically approved 
feasibility study7–9 and will utilise standard operating proce-
dures successfully validated in Malawi. The study follows a logi-
cal sequence and the detailed schedule of visits (12 scheduled 
visits - Visit A to Visit L) and procedures carried out at each 
visit are described in Table 1.
The sequence of stages followed is:
1.     Screening and recruitment: Potential participants will be 
screened to ensure health and safety (Extended data16) as 
detailed in the Methods section.
2.     Randomisation: Participants will be allocated to vacci-
nation with PCV-13 or normal saline vaccination in ran-
domised blocks (1:1 randomisation PCV13 vs. normal saline, 
double-blinded).
3.     Post vaccination samples: Samples will be taken to 
confirm nasal carriage status and measure immune response.
4.     Primary inoculation: Participants will be inoculated with 
S. pneumoniae serotype 6B to the inside of each naris. 
We will sequentially increase the inoculation dose (20,000, 
80,000 and 160,000 colony forming units per naris). One 
hundred and forty participants will receive the 80,000 dose 
to facilitate direct comparisons with our completed UK 
study6. Forty participants will receive the 20,000 dose and 
twenty participants will receive the 160,000 dose. Total 
participants = 200.
5.     Detection of pneumococcal carriage: Nasal wash samples 
will be taken, according to a standardized protocol, at days 
2, 7, and 14 days post inoculation. Classical microbiological 
culture will determine nasal colonisation with pneumococcal 
serotype 6B at each time point.
6.     Immunology response measurements: Blood, mucosal 
and nasal cell samples will be taken to determine the 
immunological response to nasal challenge.
7.     Re-screen and recruitment: Participants will be invited 
to be re-challenged with pneumococcus. We will re-screen to 
ensure health and safety as detailed in Methods.
8.     Final inoculation: Participants will be inoculated with 
S. pneumoniae serotype 6B to the inside of each naris (as 
per stage four). We will use a single dose of 80,000 cfu/naris. 
9.     Detection of pneumococcal carriage: Nasal wash samples 
will be taken, according to a standardized protocol, at days 
2, 7, and 14 days post inoculation (as per stage five). 
Classical microbiological culture will determine nasal 
colonisation with pneumococcal serotype 6B at each time 
point.
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Study endpoints
Primary endpoint: detection of the inoculated pneumococci 
by classical culture methods, at any time point, from nasal wash 
recovered from the participants at days 2, 7 and 14 following 
the initial pneumococcal challenge.
Secondary endpoints: Pneumococcal carriage density and dura-
tion will also be measured to inform the primary endpoint. 
Innate, humoral and cellular responses to pneumococcal 
colonisation will be assessed by immunological assays on 
collected samples. These data will allow us to define the host 
variables that predict colonisation and protection due to PCV-13 
vaccination.
Social science evaluation: An exit questionnaire (Extended 
data17) will be conducted as part of visit G and visit L to monitor 
Table 1. Study procedures and sampling schedule. Study visit A may occur for up to 
one month before study visit B. There will be a flexibility of up to 10 weeks after study 
visit B (1–11 weeks) to allow for staggering to inoculate a safe number of participants per 
week. Thereafter, the schedule will fix as per the table (e.g. if study visit D occurs at week 
9, then E will be at 9, F at 10 and so on). There will be a further flexibility ± two weeks at 
visit H to facilitate appointment booking. There will be a tolerance of ± two working days 
for study visits F, G, K and L. FBC: full blood count; U&E: urea and electrolytes; PBMCs: 
peripheral blood mononuclear cells; RNA: ribonucleic acid. *This is for immune measures 
(transcriptomics) and is not a genetic test. Pregnancy test for female participants only.



















































H I J K L
Study Week 1 5 6 6 7 8 53 54 54 55 56
Day post 
inoculation
0 2 7 14 0 2 7 14
Consent (Written) x x
Consent (Verbal) x x x x x x x x x x x x
Clinical Exam x x
Vital Signs x x x x x x x x x x x
Medical History x x




HIV test x x x
Pregnancy test x x x
FBC (2.5ml) x x
PBMCs (18ml) x x x x x x x x x
Serum (2.5ml) x x x x x x x x x
Blood RNA (2.5ml)* x x x x x
Nasosorption x x x x x x x x x x x
Nasal Wash x x x x x x x x x
Nasal cells x x x x x x x x x
Throat swab x x x x x x x x x
Saliva x x x x x x x x x
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participant satisfaction and acceptability of the study and 
procedures. Purposeful sampling will be conducted on a subset 
of individuals to explore acceptability in more detail. This work 
will focus on perceptions of and concerns about controlled human 
infection; experience of engagement activities and consent 
processes; and participant recommendations for future research.
Study setting
Clinical procedures will be conducted at the Queen Elizabeth 
Central Hospital Research Ward, Blantyre, Malawi. Laboratory 
procedures will be conducted at the adjacent Malawi-Liverpool 
Wellcome Trust (MLW) Clinical Research Programme 
Laboratories.
Recruitment target
We will recruit 200 healthy adult participants to complete the 
study.
Duration
Recruitment of all participants and follow up will be completed 
within 28 months.
Participants, schedule and timelines
We will inoculate healthy adult participants who do not smoke 
tobacco or other products (including electronic cigarettes) 
with a well-characterised, fully sequenced penicillin-sensitive 
pneumococci and observe them for the development of 
pneumococcal carriage up to 14 days post inoculation. 
Study discharge will occur after visit G (day 14 post inoculation 
– see Table 1). Participants will be invited to attend for 
re-recruitment leading to re-inoculation twelve months after 
vaccination (visit H – see Table 1). This process will include 
repeated participant information delivery and health screening 
procedures to confirm informed consent and continued health 
status (Extended data16). The visit schedule is also described 
in detail in Figure 1 and Figure 2.
Study visits must take place according to the proposed 
sequence in order to ensure participant safety. This will be 
clearly explained to the participants during recruitment and con-
sent (Extended data16). If a participant is unable to comply, they 
will not be recruited. Daily phone contact occurs between 
study visits until day seven post-inoculation.
Participant recruitment
Advertisements inviting healthy participants to participate 
will be widely placed. Areas will include physical notice boards, 
table display, electronic notice boards, the intranet/internet 
of local universities and colleges (with permission), social media, 
the local press, television and radio. Staff from the MLW team 
will be permitted to participate providing they are study team 
members.
Interested persons will be asked to contact the research team 
by text for further information. Once potentially interested 
participants have contacted the research team, they will then 
be invited to meet a member of the research team (information 
dissemination – visit A, Table 1). A research team member will 
explain the study at the meeting and the Participant Information 
Sheet will be provided. Participants will then consider if they 
wish to continue (see Table 1).
At visit B, the informed consent process will be conducted by 
either a research nurse or research doctors (Extended data16) 
who are formally delegated by the Chief Investigator, trained in 
good clinical practice (GCP), consent and the trial protocol. 
Following consent, inclusion and exclusion criteria will be applied 
as below.
Inclusion criteria
     •      Adults aged 18–40 years - ages chosen to minimise the 
risk of pneumococcal infection
     •      Fluent spoken and written Chichewa or English - to 
ensure a comprehensive understanding of the research project, 
their proposed involvement and communication with all 
members of the research team
Exclusion criteria
     •    Previous pneumococcal vaccination
     •     SARS-CoV-2 RT-qPCR (Polymerase Chain Reaction) 
positive at screening or any subsequent visit
     •     HIV-infection seropositive. HIV self-test kits will be 
used by participants to confirm infection status in the 
presence of the research team. Any seropositive partici-
pant will be referred to trained personnel certified in HIV 
Testing Services (HTS) for confirmatory “Determine” 
and “Unigold” tests. Any participants confirmed as 
HIV-infection positive will be referred to the govern-
mental system for infection confirmation, treatment and 
follow up.
     •     Close physical contact (e.g. sleeping in the same room 
or nursing) with at-risk individuals (children under 
5 years age, immunosuppressed adults, elderly, chronic ill 
health)
     •     Allergy to penicillin/amoxicillin
     •     Acute illness
                 ○   Current illness
                 ○   Acute illness within 3 days prior to inoculation
                 ○   Antibiotic treatment within 2 weeks of inoculation
     •      Chronic illness that may impair immune response or 
impair   ability to comply with study procedures and safety 
monitoring (e.g. HIV, diabetes).
     •      Taking immunosuppressive medication that may include 
but is not limited to steroids and steroid nasal spray.
     •     Pregnancy - minimise risk of pneumococcal disease
     •      Involved in another clinical trial unless observational or 
in follow-up (non-interventional) phase
     •      History of drug or alcohol abuse. This is very difficult 
to ascertain in a history therefore we will exclude 
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Figure 1. Visit schedule for Phase 1 of the study.
Figure 2. Visit schedule for Phase 2 of the study one-year post vaccination. Participation in phase 2 is not mandatory. An additional 
consent procedure will be required prior to participation in this phase.
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people reporting drinking alcohol more than twice per 
week.
     •     History of smoking
                 ○      Current regular smoker (smokes daily/ smokes > 5 
cigarettes per week) - minimise risk of pneumococcal 
disease
                 ○      Recent smoker, i.e. within the last 6 months - minimise 
risk of pneumococcal disease
                 ○      Ex-smoker with a significant smoking history 
(>10 pack years) – minimise risk of pneumococcal 
disease
     •    Unable to give informed consent
     •      In case of any uncertainty or concern, the principal 
investigator (PI) will take clinical responsibility for the 
decision.
     •      Participant is positive for S. pneumoniae serotype 6B on 
nasal wash sample at visit C. Current natural carriage 
of serotype 6B would preclude determination of our 
primary outcome.
Screening and preliminary assessment
Following consent, inclusion and exclusion criteria, data and 
samples will be collected.
•      Initial clinical examination will include a focused clinical 
history and targeted clinical examination involving 
auscultation of the lung fields and heart sounds. Participants 
will be informed if their clinical examination is normal. Should 
a previously unrecognised abnormality be identified, this will 
be explained to the individual, and appropriate investiga-
tions and follow-up will then be arranged by the study team. 
Further participation will be determined at the discretion of 
the study doctor dependent on the nature of the abnormal-
ity detected. If the participant is not eligible due to an acute 
illness, they may be re-screened at a later date with their 
verbal consent.
•      Blood samples will be obtained using venepuncture by 
an appropriately trained team member. A maximum of 
100mL of blood will be collected in each phase of the study 
(total 200mL if participant consents to re-challenge after 
one year) for analysis including a full blood count. The vol-
ume of blood collected for each laboratory test is detailed 
in Table 1. Participants with an abnormal full blood count 
will be excluded from the study as determined by the clinical 
team.
•      Nasosorption will be obtained before the nasal wash. 
The strips are similar to blotting paper and developed by 
Hunts Development Ltd (UK). Strips collect concentrated 
nasal lining fluid before the nasal wash to measure inflamma-
tory responses induced by infection that may be associated 
with increased colonisation density and acquisition. 
Concentrated nasal fluid will be used to measure cytokine 
levels by multiplex bead array. Blotting paper will be held 
inside the nostril for up to 3 minutes until soaked. These will 
then be removed and placed in a microcentrifuge tube for 
storage.
•      Nasal wash will be performed using an established 
method18. This is a well-used and validated technique to 
collect nasal bacterial specimens used successfully during 
our feasibility study. Briefly, 5ml of sterile saline is instilled 
and held for a few seconds in the nares before being expelled 
into a sterile Galli pot. This is repeated twice in each naris 
using 20ml saline in total. In the event of nasal wash loss 
(defined as cough/sneeze/swallow), the procedure may then 
be repeated to obtain an adequate specimen. Should the 
nasal wash reveal natural colonisation of pneumococcus, the 
participant will continue in the study and receive the 
inoculation as per protocol, unless the natural serotype is 
identified as 6B, in which case the participant will be 
excluded from the study prior to inoculation (primary outcome 
cannot be determined). All pneumococcal carriage negative 
participants will continue in the study.
•      Nasal cells will be collected using a nano-sampling method 
in which cells are obtained through minimally invasive 
superficial nasal scrape biopsies (Rhino-Pro Nasal Curette, 
Morphew Curettes). Experience from our feasibility study7 
demonstrates that participants can be biopsied multiple 
times with no significant side effects. Nasal cell samples 
will be obtained after nasal wash samples have been taken. 
Up to 4 samples (2 per nostril) will be obtained at each nasal 
sampling visit. If the researcher finds that the sample is 
insufficient, for example no cells are visible on the 
rhinoprobe, the sample can be repeated immediately. 
The rhinoprobes are placed in transport media immediately 
after collection.
•      Throat swabs will be performed by simple posterior 
pharyngeal swabbing on a dry swab and placed into cul-
ture media. This test will be used to determine viral 
co-infection (including COVID-19).
•      Saliva will be collected by a salivette held for saturation 
or a spit in the tube.
•      Urine sample will be taken for a pregnancy test as part 
of the safety screening. 
Pneumococcal inoculation
Preparation of bacterial stock and inoculation
•     Initial preparation and transfer to MLW: Microbiological 
and sequence confirmation of the purity of the inoculum will 
take place at LSTM and reference Public Health England 
laboratories prior to the onset of the study. Once complete, 
the microbiologically and genetically confirmed S. pneumo-
niae capsular serotype 6B strain BHN418 will be transferred 
from the LSTM to MLW. Microbiological and serotype 
confirmation will take place at MLW upon receipt.
•     Preparation of bacteria for carriage studies at MLW: 
LSTM will provide MLW with mid-log broth cultures of 
pneumococcus, frozen at -80°C in aliquots of glycerol-enriched 
media. Immediately prior to participant inoculation, aliquots 
will be thawed, washed twice, and re-suspended in sterile 
saline at an appropriate density for each inoculation dose. 
Our validated Standard Operating Procedure (SOP), based on 
LSTM protocols, will be used.
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•     Confirmation of accuracy: Following culture by the 
laboratory team at MLW, aliquots of the bacterium will be 
returned to the UK, as a quality control measure, to confirm 
the identity, purity and penicillin sensitivity of the isolate. 
These bacterial isolates will be sequenced in the UK to confirm 
identification.
•     Regulatory approval: S. pneumoniae transfer will be 
reported to the Malawian Pharmacy, Medicines and 
Poisons Board (PMPB, national regulatory authority) prior 
to initiation of the study. For our feasibility study, PMPB 
confirmed through the NHSRC that Malawi would adopt the 
UK Medicines and Health care products Regulatory Authority 
(MHRA) position that controlled human infection inoculation 
with pneumococcus is not an investigational medicinal 
product. PCV13 is an investigational medicinal product and 
has been approved by the Malawi Pharmacy and Medicines 
Regulatory Authority (PMRA: 10062020121) for this trial.
•     Inoculation: Using a P200 micropipette, 0.1ml saline 
containing the desired dose of pneumococcus will be 
instilled into the nose. The participant will be seated in a 
semi-recumbent position. After inoculation, the participant 
will remain in this position for up to 15 mins. They will be 
given a post-inoculation advice sheet (including emergency 
contact details), thermometer, a course of amoxicillin and a 
daily symptom log to complete.
•     Dose escalation: We will adopt a stepwise approach to 
escalating the inoculation dose: 20,000 (n=40) → 80,000 
(n=140) → 160,000 (n=20). We previously demonstrated 
successful carriage and safety at the 20,000 and 80,000 
doses in our feasibility study7–9 and the 160,000 has been 
safely used in the Liverpool with no adverse events12.
Randomisation
Participants will be individually randomized to either 
PCV-13 (Prevenar) or normal (0.9%) saline vaccination prior to 
primary inoculation. A random number generator will be used 
to generate the randomization sequence and randomization 
occurs using block randomization with random block sizes 
of 6, 8 and 10 to ensure balanced vaccine allocations. 
An independent statistician will run the randomisation code 
for study group allocations and allocations will be stored on a 
secure electronic portal at MLW. The research team will be 
blinded to the vaccination group. Procedure: The study 
pharmacist will be fully unblinded and prepare each PCV-13 
or normal saline according to the randomisation code. 
Individual doses will be prepared to maintain research team 
and participant blinding. Individual doses will be identified 
only by a randomisation identification number and barcode. 
Participants will be randomised on an electronic tablet 
immediately after screening is completed and they are 
confirmed eligible. The tablet will hold the randomisation 
identification number and barcode details. Subsequently, the 
vaccine barcode will be electronically confirmed against the 
participant identification number using the electronic tablet 
prior to administration. Unblinding will occur once microbio-
logical reporting is completed for the final participant at visit G 
(14 days after primary inoculation). Participants entering the 
second stage (visit H) of the study will therefore be unblinded.
Vaccines
The vaccines will be purchased by the MLW clinical tri-
als pharmaceutical team. The vaccines will be stored at the 
appropriate temperature and administered as per manufacturer’s 
instructions. Prevenar-13 will be purchased from Pfizer 
Pharmaceuticals and administered in a single dose via intra-
muscular injection (0.5mL supplied in a prefilled syringe). 
The normal (0.9%) saline will be administered as a single 
dose (0.5mL) by intramuscular injection. The vaccines will be 
administered by experienced, trained health care professionals 
from MLW. Participants will be observed for 20–30 minutes 
following vaccination to ensure that they do not experience 
a reaction to the vaccine. If any adverse reaction occurs the 
volunteer will be transferred to the Queen Elizabeth Central 
Hospital High Dependency and Respiratory Unit (HDRU) or 
the Adult Emergency and Trauma Unit (if HDRU capacity is 
limited) and the study team informed. Immediate un-blinding 
will occur in the event of an adverse event requiring medical 
attention for which knowledge of the vaccine given will affect 
treatment and ongoing immediate care.
Normal saline has been chosen as a suitable control due to its 
long-established safety profile in vaccine trials and lack of 
effect on nasal colonisation/immunity. Sterile 0.9% saline 
vaccination is commonly used as a control for vaccine trials 
including in sub–Saharan Africa19 and in a recently published 
COVID vaccine study20. Sterile saline is licensed for use for 
dissolving drugs for IV, IM and SC injection and used commonly 
in clinical practice. Whilst injection with saline will not confer 
any benefit, participants will be offered PCV13 vaccination after 
unblinding and completion of the day 14 sample following final 
inoculation in phase 2 (week 56). PCV13 will also be offered 
to participants who do not take part in the second phase of the 
study (decline consent or ineligible after re-screening). 
Determination of colonisation
Colonisation will be defined by the microbiology result of 
nasal washes taken at 2-, 7- and 14-days post inoculation. 
Nasal washes will be plated on to culture media and incubated 
overnight at 37°C in 5% carbon dioxide (CO
2
). Colonies will 
be confirmed as S. pneumoniae using classical microbiological 
techniques including (i) typical draughtsman-like colony 
morphology, (ii) the presence of α-haemolysis, (iii) optochin 
sensitivity and (iv) bile solubility. Typing by latex agglutination 
will be done using a commercial kit to confirm pneumococcal 
serogroup. Isolates will be frozen at -80oC for storage. Results 
from the cultured nasal wash will also be confirmed using 
PCR based methods of bacterial detection.
Monitoring of colonisation will be performed by microbiology 
analysis of nasal washes. This will include measurement of 
pneumococcal density by LytA PCR. Monitoring for COVID-19 
co-infection will be performed by RT-qPCR analysis of throat 
swab samples
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Safety during colonisation
A three-day course of amoxicillin and a digital thermometer 
will be given on the day of inoculation. These will be car-
ried by the participants for immediate treatment after phone 
consultation should the participant develop moderate or severe 
symptoms as described on the participant safety advice leaflet. 
Participants will be required to make text message/phone 
contact with a specified member of the research team before 
1200 hrs every day for 7 days post-inoculation regardless of 
whether they have symptoms or not. Should they not make contact 
by the specified time, a member of the research team will 
contact the participant. If no contact is made, then a ‘secondary 
contact’ (established during screening visit) will be telephoned. 
During the post-inoculation period, participants will have 
access to a 24/7 on-call telephone service until the end of each 
phase (H and L) of the study.
Termination of carriage
All study participants who are nasally colonised with 
pneumococcus serotype 6B at the end of the study will be asked 
to take oral amoxicillin 500mg three times daily for 3 days. 
This will be communicated at visit G, or by telephone in the 
unlikely event of only visit G samples (day 14 – see Table 1) 
showing carriage.
Immunological assays
•     Antibody titres: measurement of pneumococcal-specific 
protein and polysaccharide antibodies will be conducted 
on nasal wash, salivary and serum samples using ELISA as 
previously reported21. This will allow us to identify poten-
tial antibody correlates of protection against pneumococcal 
colonisation.
•     Cellular responses: measurement of pneumococcal-specific 
memory B and T cells will be performed on peripheral blood 
and nasal samples using flow cytometry and ELISPOT as 
previously reported22,23. This will allow us to identify potential 
cellular correlates of protection against pneumococcal 
colonisation. 
•     Cytokine profiles: measurement of cytokines will be done 
on nasosorption and serum samples using multiplex bead 
array as previously reported24. This will enable us to iden-
tify potential soluble marker correlates of protection against 
pneumococcal colonisation.
•     Host transcriptomic analysis: measurement of host nasal 
mucosa transcriptomic profile will be done using RNA 
sequencing (RNAseq) on nasal cells and peripheral blood 
as previously reported22. This will allow us to characterise 
potential nasal or blood transcriptomic signatures associated 
with protection or susceptibility to pneumococcal carriage.
•     Microbiome profiles: characterisation of microbial 
communities will be done on throat swabs and nasal washes 
using next-generation sequencing and metagenomic analysis 
as previously reported24.
Sample size justification
The primary endpoint is the occurrence of pneumococcal 
colonisation determined by the presence of pneumococcus in 
nasal wash samples at any time point post inoculation detected 
using classical microbiology. Secondary endpoints will include 
density and duration of pneumococcal carriage in nasal wash.
Based on the pneumococcal dose of 80,000 cfu/naris and 
using data from our feasibility study7,8 and Liverpool-based 
studies6, we estimate that 60% of the control (normal saline) 
group will be colonised with pneumococci following inoculation 
and 36% of the PCV-13 group, this equates to a 40% reduction 
in colonisation. We observed a 78% reduction in the UK based 
study6. However, as Malawian data demonstrates decreased 
efficacy for PCV-13 in carriage reduction10, we have powered 
the study at approximately half of this effect size. Based on 
these parameters, we will randomise 67 participants per arm for 
80% at a 5% significance level (see Table 2). To correct for 
any potential drop out, we will randomise 70 participants to each 
arm (total 140 participants for primary outcome).
An additional 40 participants will be randomised (1:1, PCV13 
vs. normal saline) at the 20,000 pneumococcal dose. A further 
20 participants will be randomised (1:1, PCV13 vs. normal 
saline) at the 160,000 pneumococcal challenge dose. These 
doses will be used to explore the effects of differential 
pneumococcal exposure on PCV-13 vaccine efficacy. Recent 
methodological developments in vaccine efficacy estimation 
highlight important gains derived from the use of multiple-dose 
over single-dose experimental designs25. By extending our core 
experiment with smaller groups of participants at doses below 
and above 80,000 CFU, we will be in a position to not only apply 
the new methods to a human system for the first time, but also 
test their performance against a previously established mathe-
matical model25. Participant consent is required before screening 
procedures can be conducted. Any participant who consents 
but is subsequently determined to be ineligible will be replaced 
so that a total of 200 participants will be inoculated with 
Streptococcus pneumoniae for the first phase of the study. 
Important secondary endpoints including the immune 
responses, in particular humoral and cellular responses, will 
also be assessed. Immunological parameters will be compared 
between pre-vaccination and pre-inoculation values in paired 
analyses using parametric or non-parametric tests as appropriate.













67 0.6 0.45 0.25 0.41
67 0.6 0.42 0.30 0.55
67 0.6 0.39 0.35 0.69
67 0.6 0.36 0.40 0.80
67 0.6 0.33 0.45 0.89
67 0.6 0.30 0.50 0.95
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Analysis plan
The reporting of this study will be prepared in accordance to 
the CONSORT 201026 guidelines. A CONSORT diagram will 
summarise participant screening, enrolment, randomisation, 
inoculation, withdrawals, follow-ups and analysis. All con-
tinuous data variables will be summarized using the following 
descriptive statistics: N (size of relevant analysis population), 
n (size of analysis population without missing values), mean, 
standard deviation, median, 25th percentile value, 75th percen-
tile value and interquartile range, minimum and maximum. 
The proportion of observed levels will be reported for all binary 
and categorical measures. When appropriate, corresponding 
exact, binomial 95% confidence intervals for proportions will 
be included.
The primary endpoint is the occurrence of pneumococcal 
colonisation determined by the presence of pneumococcus in 
nasal wash samples at any time point post inoculation detected 
using classical microbiology. Secondary endpoints will include 
density and duration of pneumococcus in nasal wash. While 
140 participants will be randomised (1:1, PCV13 vs. normal 
saline) at the 80,000 CFU pneumococcal dose, an additional 
40 participants will be randomised (1:1, PCV13 vs. normal 
saline) at the 20,000 pneumococcal dose and a further 
20 participants will be randomised (1:1, PCV13 vs. normal saline) 
at the 160,000 pneumococcal challenge dose.
The primary endpoint will be analysed using generalised 
linear models (GLMs; log-binomial or, in case of convergence 
issues, logistic regression) with treatment as a single predictor, 
generating risk ratios and odds ratios together with their 
95% confidence intervals of being colonized with pneumo-
coccus between the PCV13 and normal saline control groups. 
We will use longitudinal data analysis methods, specifically 
generalised linear mixed models (GLMM) or generalised 
estimating equations (GEE), to analysis pneumococcal carriage 
status and density at individual time points with treatment, 
time and interaction between time and treatment as fixed effects 
and study participant as random effect / clustering variable.
Immunological parameters will be compared between PCV13 
and placebo recipients, as well as between carriers and 
non-carriers using similar methods (GLMs for comparing 
parameters according to overall carriage status and/or treat-
ment, GLMMS/GEEs for longitudinal analyses). The area under 
the curve (AUC) of pneumococcal colonization at days 2, 7 
and 14 post inoculation will be calculated using the trapezoidal 
rule and the AUC will be analysed using a GLM with a single 
factor for treatment.
The effects of differential pneumococcal exposure on PCV-13 
vaccine efficacy will be analysed using recent methodology 
developed by our team25. Expanding vaccine efficacy estimation 
with dynamic models fitted to cross-sectional prevalence data 
post-licensure. All quantitative analyses will be conducted in the 
intention-to-treat population. Analyses will be conducted using 
the R environment for statistical programming and computing 
(v4.0.0 or higher). All computer code will be made publicly 
available on GitHub under a CC BY 4.0 license.
The social science evaluation requires qualitative data to 
understand volunteer perspectives of benefits, challenges, 
tolerability of study procedures, and any potential unintended 
effects through the study. All participants will be asked to 
complete an exit questionnaire upon completion of visit G 
(and visit L if consented for the second phase of the study) 
(Extended data27). This questionnaire will be completed 
by the participant on a tablet computer. Any participant who 
expresses concern(s) or dissatisfaction will be offered the 
opportunity to discuss in more detail as part of a semi-structured 
exit interview conducted as a separate appointment.
In the event that there are several structured exit interviews, 
all data collected will be audio-recorded and transferred to a 
qualitative data analysis software package (NVIVO), to 
enable analysis. Data will be analysed following broad 
deductively defined themes and inductively derived sub-themes. 
We will employ a combination of thematic coding in NVivo 
and use of frameworks to compare perspectives between 
different stakeholders (participants and study team members). 
Two researchers will undertake initial coding of an initial small 
number of transcripts, and then discuss and agree themes for 
further coding in the event that there are any further transcripts. 
Analysis will be on-going during fieldwork, using an itera-
tive approach to identify emerging themes that can be 
clarified or explored further through later data collection. 
Data will be triangulated between methods and partici-
pant groups to cross-check information and provide a more 
comprehensive analysis. At this point, given responses in the 
feasibility study, we consider it unlikely that there will be a 
significant volume of exit interview material to analyse.
Safety considerations and assessment
Study design to ensure safety. Safety is paramount in human 
infection studies. While the risk to individuals of develop-
ing any infection is very low (40% Malawian adults experience 
natural colonisation at any time, and the incidence of invasive 
disease is 20/100 000 patient years28), the study is designed to 
ensure any risk is minimal by appropriate:
     •     Study team selection and rigorous training in human chal-
lenge procedures
     •      Study design with staggered recruitment approach (sample 
size and dose)
     •      Careful serotype selection, demonstration of safety and 
acceptability in our feasibility study and 10 years of 
pneumococcal controlled human infection experience at 
LSTM
     •     Participant selection and exclusion criteria as detailed
                 ○     Including exclusion of COVID-19 positive 
participants at screening visit and continued 
monitoring for infection at day 2, 7 and 14 after 
inoculation
     •      Participant education through a participant information 
sheet (provided)
     •      Rigorous safety procedures including daily monitoring 
and providing participants with a thermometer and a course 
of amoxicillin tablets in case of emergency
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     •      24-hour emergency telephone contact with researchers, 
including close individual daily monitoring, and access to 
hospital facilities and prompt treatment if required
     •      To further mitigate risk, participants will be provided 
with accommodation for three nights immediately 
following nasal challenge. If a participant determines 
that it is not possible to stay at study accommodation for 
three nights then a pragmatic approach to further study 
procedures will be taken. If the participant can demonstrate 
that they remain readily available by phone and acces-
sible with transport, this need not affect the procedure. 
Twice daily checks could replace the resident period. 
In the Liverpool CHIM there is no resident period 
at all. If, however, the participant absconds or is intend-
ing to be uncontactable, then participation in the study 
will be stopped and antibiotics offered as at the end of the 
protocol.
We will schedule inoculations such that visit G is completed 
for each pneumococcal dose group (20,000 and 80,000) before 
progression to the next group (80,000 and 160,000 respectively).
The research investigators have successfully worked together 
to safely deliver our pneumococcal CHIM feasibility study in 
Malawi based on knowledge and experience from the 
Liverpool studies7. No episodes of pneumococcal infection or 
serious unexpected serious adverse reactions (SUSARS) have 
occurred in any of our participants whether they had no carriage, 
natural carriage or experimental carriage.
Vaccine safety. Prevenar-13 is a safe vaccine with a very low 
risk of adverse events29,30. It is currently licensed for use in 
children and in Malawi as part of the Childhood Immunisa-
tion programme (effective from 2011). In adults over 50 years of 
age vaccinated in US clinical trials the most commonly reported 
side effects to Prevenar-13 vaccination included: injection site 
pain/swelling/tenderness, fatigue, headache, muscle pain, 
limitation of arms movement, decreased appetite, chills and rash.
Normal (0.9%) saline is commonly used for control vaccination 
in vaccine efficacy trials. Normal saline is licensed for IV, IM 
and SC injection and is safe with minimal side effects20.
Participants will be observed by trained research staff in the 
research clinic rooms after vaccination for a period of 20–30 
minutes. This procedure is to mitigate the very low risk of any 
immediate drug reaction. The 3A research clinic rooms are situ-
ated directly opposite to a respiratory high dependency unit at 
Queen Elizabeth Central Hospital. In the unlikely event that 
a participant became unwell after vaccination, they would be 
transported to this ward for treatment and close monitoring.
Participant safety procedures. We will provide all partici-
pants with a safety information sheet31. This sheet classifies 
symptoms into mild, moderate and severe. We will take a 
proactive approach for participants, with daily contact up until 
day seven post inoculation and enquiry about development of any 
symptoms. We will also encourage participants to report 
development of any symptoms with 24-hour medical cover 
throughout the study visit schedule. In the event of illness, we will 
apply standardised operating safety procedures for participants. 
The research team will pay for any costs associated with these 
procedures and participants will incur no out of pocket expenses.
Mild illness. Mild illness is defined as development of any new 
symptom that is of concern to the participant during the study 
period. These may include mild coryzal symptoms such as 
blocked or runny nose. Participants will be encouraged to 
contact the research team by telephone within office hours. 
During the telephone assessment participants will be screened 
for potentially concerning moderate and severe symptoms. 
If there is any concern, participants will be invited to the research 
clinic for a detailed clinical assessment by one of the study 
doctors. The assessment will be fully documented within study 
records including rationale for any treatments and/or required 
modifications to study procedures.
Moderate Illness. Moderate illness events are defined as fever 
with temperature >37.5ºC, shivering, headache, new rash, 
drowsiness, cough, new earache and or new eye infection. Par-
ticipants will be clearly instructed to call the research team at 
any time of the day upon development of any of these symptoms. 
During the telephone assessment participants will be screened 
for severe symptoms and requested to attend either the research 
clinic (office hours) or Mwaiwathu hospital (outside of 
office hours) for medical assessment. If severe symptoms are 
identified on telephone assessment, participants will be asked to 
take antibiotics from their supplied emergency pack and attend 
Mwaiwathu hospital. Study doctors will assess the participants 
at either the research clinic or Mwaiwathu and offer appropriate 
treatments. The assessment will be fully documented within 
study records including rationale for any treatments.
Severe illness. Severe illness events are defined as any 
symptoms that cause serious concern to participants following 
inoculation. We have purposefully taken a conservative approach 
to encourage participants to seek early medical advice and 
treatment if they are concerned. Participants will be coun-
selled as to what symptoms the study team may be particularly 
concerned about during the consent process. These would include 
any potential symptoms of sepsis. In the event of severe illness, 
participants are requested to start taking the provided 
emergency antibiotics, directly attend Mwaiwathu hospi-
tal and contact the study team. A study doctor will attend the 
patient in Mwaiwathu and offer appropriate treatments. The 
assessment will be fully documented within study records 
including rationale for any treatments.
COVID-19 specific participant safety procedures. Partici-
pants who screen positive for COVID-19 will be excluded from 
the study. The study team will offer standardised advice to such 
participants including self-isolation measures to reduce 
onward transmission in line with Malawi Ministry of Health 
guidance32. After an initial negative test, we will continue 
to screen participants for development of COVID-19 after 
Page 13 of 19
Wellcome Open Research 2021, 6:240 Last updated: 15 NOV 2021
pneumococcal inoculation at visits 4, 6 and 7. No additional 
samples will be required, we will use throat swabs to test for 
COVID-19 using RT-qPCR in line with CDC guidance33. 
Participants will be notified if they become positive for 
COVID-19 during the study and excluded from further visits. 
This procedure is to facilitate self-isolation in line with guidance 
and to reduce the risk of transmission. If the participant 
has concurrent pneumococcal carriage, they will be advised 
to commence antibiotics to reduce the theoretical risk of 
bacterial co-infection. We will replace participants who are 
excluded during post-inoculation follow up to recruit the 
pre-specified allocated number of patients to each group.
Evaluation of adverse events and serious adverse events
Adverse events: Non-serious adverse events (AEs) will be 
collected systematically during the research and recorded in 
the case report form. Participants will keep a log of symptoms 
and this will be summarised and reported to the Data, Safety and 
Monitoring Board (DSMB). 
Serious adverse events: Any serious (AE), as defined in 
ICH-GCP occurring to a research participant, will be reported 
to the DSMB, NHSRC and study sponsor within 24 hours of 
the study team becoming aware of the event. In this event, the 
research will be stopped temporarily for investigation and 
any further work deferred until DSMB and NHSRC advice 
has been provided to the Trial Steering Committee (TSC) for 
consideration. 
Risks to researchers: These are standard clinical (needle 
stick) and laboratory (biohazard) risks. Experienced staff will 
carry out procedures that are within their competencies in 
accordance with standard operating procedures regulated by 
good clinical practice and national guidelines. Appropriate risk 
assessments are in place for all laboratory SOPs. All labora-
tory work will be conducted in an appropriately rated laboratory 
in line with health and safety regulations for research with 
human tissues / infectious agents. All staff will be provided 
with and training in the appropriate use of personal protective 
equipment to reduce the risk of COVID-19 infection. We will use 
UK Public Health England PPE guidance recommendations34.
The Data Safety Monitoring Board (DSMB). The DSMB 
will be established prior to commencing this study and include 
members expert in controlled human infection, safety and 
statistical procedures. Prof Rob Read will Chair - Prof Read has 
chaired the LSTM DSMB for 10 years.
The DSMB will monitor the study and advise the TSC, 
including the PI and study team. Briefly, all SAEs will be reported 
to the DSMB and study sponsor within 24 hours and recruitment/
inoculation paused pending DSMB review and recommenda-
tion to the TSC in line with GCP guidelines. The study team will 
provide at least monthly update (by email) on all recruitment 
to the DSMB. The DSMB will meet formally (by telephone 
conference) biannually and in the event of any SUSARs.
Stopping criteria. This study will pause in the event of a 
SAE or on completion of the Protocol. Thereafter, DSMB and 
NHSRC members will assess the event before advising the 
Trial Steering Committee on measures required to resume the 
study or if the study should be stopped. The study will only be 
resumed if both the DSMB and NHSRC are satisfied that 
required measures are in place. If the DSMB or NHSRC 
recommends the early stopping of the study, all reasons must 
be stated clearly. If there are DSMB or NHSRC members with 
dissenting views, these must be appended to the 
recommendations. If there are no trial related serious adverse 
events, the study will stop upon completion of the protocol.
Ethical considerations
Autonomy. The participants will be given high-quality 
information that is written and spoken using common lay terms 
without jargon to allow them to understand the research objec-
tives and the risks and benefits of all procedures. They will then 
be given time to consider the information before consenting 
to any involvement. At no stage should the participant feel 
pressured or persuaded into participating in the research study.
Participants have the right to withdraw their consent and 
therefore withdraw from the study at any time without giving 
reason. If a participant withdraws from the study, we will recruit 
an alternative participant to complete the study.
Non-maleficence. Inoculation of S. pneumoniae will be as 
per the established and safe protocols and will be performed by 
highly trained staff with close supervision (24hr on call access 
to medical professionals involved in the study) and follow-up. 
Specific inclusion and exclusion criteria are set to further 
protect the participant. Experience and trained research staff will 
perform venepuncture and nasal sampling.
Beneficence. Participants will receive a health check including 
HIV-infection status assessment when taking part in this study. 
Participants also have the potential to benefit from completed 
vaccine schedules during the study. Patients randomised to 
normal saline will be offered PCV-13 upon completion of 
study related activities at visit L. In addition, participants may 
benefit from a better understanding of clinical research, they 
may also benefit from a sense of contributing to medical research 
in a valuable way. Participants will be remunerated for their time 
and inconvenience – discussed below.
Justice. This must be balanced with non-maleficence. Inclusion 
and exclusion criteria are in place primarily to protect individuals 
from undue risk.
Ethical approvals. Ethical approvals for this study have been 
granted in country by the Malawi National Health Sciences 
Research Committee (NHSRC, REF: 16/07/2519) and from a 
Liverpool School of Tropical Medicine (LSTM) institutional 
perspective (REF: 20-021).
Trial registry. This trial is registered with the Pan African 
Clinical Trial Registry (PACTR, REF: PACTR202008503507113).
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Regulatory approval. The trial has been approved by the 
Malawi Pharmacy and Medicines Regulatory Authority (PMRA/
CTRC/III/10062020121)
Remuneration
It is intended that financial factors will not significantly influence 
an individual’s decision to participate in this study. We reimburse 
participants for out-of-pocket expenses such as travel, and 
compensate time spent and burden. The sums offered in this 
study are consistent with remuneration guidelines published in 
Malawi, paid pro-rata (per activity and not dependent on study 
completion)35.
If a participant withdraws from the study early, they will be 
compensated for the parts they took part in up until the time 
they withdrew. Payments are summarised in Table 3 and Table 4, 
MK 11,000 will be paid at the end of each study visit for 
Phase 1. If the volunteer consents to participate in Phase 
2, MK 10,000 will be paid at the end of each study visit. 
For volunteers who are approached and agree to be interviewed 
for social science activities at the end of visit G and visit L 
there will be an additional MK 7000 offered to compensate 
for their time and transportation.
Confidentiality and anonymity
Only authorised members of the research team will have 
access to any personal information. Only information of direct 
relevance to the study will be collected (Extended data17). All 
electronic records containing personal information will be 
stored in a password protected database on a password protected 
server at MLW. Electronic case report form data will be 
collected on encrypted study-specific tablet devices and 
synchronised daily onto the MLW server. This approach is 
well established at MLW, and the policy governing MLW 
data management policy is available upon request. Paper 
documentation containing personal information will be kept 
in a locked filing cabinet in a locked room in the Queen 
Elizabeth Central Hospital research clinic.
Each participant will be assigned a unique non-identifiable 
study number by a member of the clinical research team at 
recruitment. Unlinked non-identifiable clinical data will be 
stored and analysed at the MLW-laboratories and collaborating 
laboratories.
For any exit interviews carried out, the following ethical 
considerations will be applied to ensure privacy and 
confidentiality is upheld. Following each interview, audio files 
will be transcribed verbatim into written Chichewa or English 
(depending on language used in interview) and translated to 
English where necessary. The research assistant responsible 
will save the audio file on a secure cloud-based network drive 
that will only be accessible to the social science team of 
researchers. Any paper copies will be stored in a locked filing 
cabinet.
Participant names will not be included in transcripts or file 
names; instead, participants will be given ID numbers. Enrolment 
logs and any consent documents that include participant names 
or contact details will be stored separately in a locked filing 
cabinet. Electronic recordings and transcripts will be stored 
on a secure cloud-based drive for a minimum of five years 
from the end of data collection, to allow data analysis, publication, 
and ability to the wider scientific community to check our results.
Samples and data
Sample and data storage. MLW will act as custodian for 
all data and samples collected during the study. Consent will 
be obtained from the participant to use the samples for this 
research only. Samples will be stored for a maximum of five years. 
Collaborating laboratories. Samples will also be sent to 
national and international collaborating laboratories to utilise 
specialist expertise not available in Malawi. Samples will be 
labelled with the anonymised study number. Consent will 
specifically be obtained from the participants to allow samples 
to be sent to our collaborators.
Social science
All participants will be asked to complete a digital questionnaire 
upon completion of study related activities at the end of 
visit G and visit L (see Table 1). If a participant expresses 
any concerns or dissatisfaction, they will be offered a follow 
up exit interview at an additional visit to explore the issue(s) 
in more detailed with a trained qualitative researcher. The inter-
view will take place on a separate date and location and with a 
qualitative researcher who has not been involved in clinical 
delivery of the study. The interview will be semi-structured 
and focused on concerns raised by the participant, lasting 
approximately 30minutes. Participants will be offered additional 
compensation for time and travel to this interview.
Dissemination of findings
The findings from this study will be disseminated amongst 
the scientific community. We intend to publish our findings in 
peer reviewed scientific journals and present data at appropri-
ate local, national and international conferences. We will produce 
a close-out report for the NHSRC at the end of the study and 
a final report once data are published. In addition, we will 
produce a lay report of our findings which will be made available 
to all participants.
Sponsorship and indemnity
Sponsorship: The Liverpool School of Tropical Medicine 
(LSTM) is the sponsor (REF: 20-021).
Indemnity: We have purchased no fault clinical trials insurance 
to cover research participants for this study. This has received 
regulatory endorsement by the Malawi National Commission for 
Science and Technology (NCST, REF: NCST/RTT/2/6).
Future development of the MARVELS programme
Success in this project will result in:
A)     Measurement of the effect of PCV13 on EHPC. If the 
EHPC method shows a vaccine effect in Malawian adults, 
this will allow consideration of CHIM methods to predict 
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Table 4. Research participant remuneration for Phase 2 (visits H-L). 
*Accommodation and board costs will be paid directly by the research team. 
Visit I will cause mild discomfort. Visits H, J, K, and L will cause mild/moderate 
discomfort.
MARVELS Research Participant Remuneration (based on Malawian 
guidelines35)
Reimburse expenses Rate in MK Number of 
events
Total
a) Transport 900 5 4,500
b) Subsistence (one meal) 1500 5 7,500




Total time travelling (hrs) 5




Table 3. Research participant remuneration for Phase 1 (visits 
A-G). *Accommodation and board costs will be paid directly by the 
research team. Participants will not receive compensation to attend the 
information visit (vist A). Visit D will cause mild discomfort. Visits B, C, E, F 
and G will cause mild/moderate discomfort.
MARVELS Research Participant Remuneration (based on 
Malawian guidelines35)
Reimburse expenses Rate in MK Number of events Total
a) Transport 900 7 6,300
b) Subsistence (one 
meal)
1500 7 10,500




Total time travelling 
(hrs)
7




Time in days (day = 8 
hours)
1000 12.5 12,500
Procedure A (mild 
discomfort)
2000 1 2,000
Procedure B (moderate 
discomfort)
6000 5 30,000
Procedure C (long or 
complex)
10000
TOTAL for study 
(Phase 1)
65,800
AVERAGE per visit 11,000
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MARVELS Research Participant Remuneration (based on Malawian 
guidelines35)
Reimburse expenses Rate in MK Number of 
events
Total
Time in days (day = 8 
hours)
1000 11.5 11,500
Procedure A (mild 
discomfort)
2000 1 2,000
Procedure B (moderate 
discomfort)
6000 4 24,000
Procedure C (long or 
complex)
10000
TOTAL for study  
(Phase 2)
49,500
AVERAGE per visit 10,000
the efficacy of novel vaccines in preventing pneumococcal 
carriage (and hence transmission) in Malawi.
B)     Determination of immunological mechanisms for observed 
differences in PCV-13 induced mucosal (nasal carriage) 
protection between UK and Malawian populations
C)     Determination of 12-month PCV-13 induced host protection 
against pneumococcal carriage
D)     A greater understanding of the potential protective effects 
of carriage acquisition against future pneumococcal challenge 
in the control group.
E)     In-country capacity building to conduct future vaccine 
testing studies
Future work will be planned to build on both of these 
anticipated outcomes by engaging with vaccine manufacturing 
companies and mucosal adjuvant programmes to develop more 
efficacious pneumococcal vaccines for the Malawian population.
Study status
At time of manuscript submission (20th August 2021), study 
recruitment has commenced with successful screening and 
randomisation of 40 participants. However, the study was paused 
due to increasing cases of SARS-CoV-2 within Malawi on the 
16th June 2021.
Future amendments to the protocol will require approval by 
the National Health Research Ethics Committee and the Sponsors.
Discussion
This study will determine if vaccination with PCV13 is 
protective against pneumococcal carriage in healthy adult 
Malawian volunteers. We have designed the study such that 
findings will be exactly comparable with a previously completed 
trial in the United Kingdom6. Expanding on this study, we will 
also determine how pneumococcal dose influences carriage in 
vaccinated participants and determine longer term protection 
against carriage 12 months after vaccination. Concurrently, 
we will investigate underpinning immunological mechanisms 
for disease susceptibility to inform the discovery and 
development of new vaccine candidates. Generation of these 
data are vital to understand observed differences in vaccine 
effectiveness in the sub-Saharan African context and to inform 
the discovery and development of new vaccine candidates.
Data availability
Underlying data
No data are associated with this article.
Extended data
Harvard Dataverse: EHPC Safety Leaflet. https://doi.org/10.7910/
DVN/3LEAYH31
Harvard Dataverse: MARVELS PCV13 Data Collection Forms. 
https://doi.org/10.7910/DVN/PUEH0X17
This project contains the following extended data:
     •     Exit questionnaire
     •    Screening questions
     •     Visits question schedule
Harvard Dataverse: MARVELS PCV13 Participant information 
and consent forms. https://doi.org/10.7910/DVN/4PHN2H16
This project contains the following extended data:
     •     Phase 1 Consent Form
     •     Phase 2 Consent Form
     •     Phase 1 Participant Information Leaflet
     •     Phase 2 Participant Information Leaflet
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Reporting guidelines
Havard Dataverse: SPIRIT checklist for ‘The influence of 
pneumococcal conjugate vaccine-13 on nasal colonisation in a 
controlled human infection model of pneumococcal carriage in 
Malawi: a double-blinded randomised controlled trial protocol’. 
https://doi.org/10.7910/DVN/1QAUYA27
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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